Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 21;10(3):e003883. doi: 10.1136/jitc-2021-003883

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Somatic genomic alterations and methylation profiles related to tertiary lymphoid structure (TLS) status in kidney cancer. (A) alteration landscape of 43 primary clear cell renal cell carcinoma (ccRCC) tumor samples. upper heatmap: sex, patient age, tumor stage, nuclear grade, disease recurrence, overall mortality, and TLS status. (B) genomic alterations in tumorigenic signaling pathways related to ccRCC development in terms of TLS status. The table shows the percentage of samples with alterations in each of the selected signaling pathways.(C) Heatmap of DNA methylation data using selected probes with a DiffScore ranking in the top/bottom 50 of TLS-positive (n=13) vs TLS-negative (n=26) ccRCC tumors.(D) Go analysis using genes hypermethylated in ccRCC tumors with TLSs. BP, biological process; CC, cell component; EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; MET, mesenchymal-epithelial transition; MF, molecular function.